Boditech Med

• Q1 2025 consolidated revenue reaches $28.7 million (₩39.1 billion), operating profit $5.9 million (₩8.1 billion)
• Sales in MENA region grow over 40%; Africa and Latin America surge by more than 100%
• Marks the first year of strategic expansion into biochemistry, hematology, and veterinary diagnostic

Boditech Med, a global leader in point-of-care diagnostics, announced on May 8 its preliminary financial results for the first quarter of 2025, reporting consolidated revenue of $28.7 million (₩39.1 billion) and operating profit of $5.9 million (₩8.1 billion). This represents a year-on-year increase of 18% in revenue and 37% in operating profit, with an operating margin of 20.7%, reflecting both strong growth and solid profitability.

Broad-based growth across global markets contributed to the company’s performance. The Middle East and North Africa (MENA) region accounted for 25% of total revenue, growing by more than 40% compared to the same period last year. Markets in Africa and Latin America, which had previously shown weaker performance, rebounded sharply with sales more than doubling year-on-year.

Product portfolio diversification also drove performance. Sales of diagnostic products for vitamin D and anemia (Hemochroma) surged, resulting in over 140% growth in the “Other Conditions” category. Diagnostic kits for diabetes and hormonal disorders also posted growth exceeding 30%, while kits related to cancer and rheumatoid arthritis recorded notable gains.

The company’s diagnostic equipment segment continued to perform well, with over 3,200 new systems installed during Q1. More than 2,000 units of its flagship ichroma™ and AFIAS platforms, both equipped with multi-analyte functionality, were deployed. If this pace continues, annual installations could exceed 10,000 units, surpassing the pandemic-era average of approximately 9,000 units per year (2020–2021).

Eui-yeol Choi, CEO of Boditech Med, stated:

“We have prioritized quality enhancement across both diagnostic devices and cartridges. With our ongoing expansion into developed markets since 2023, quality competitiveness is no longer optional but essential. This aligns with the growing global demand for point-of-care testing in the post-COVID era, further strengthening our global presence.”

He added:

“2025 marks a pivotal year of transformation for Boditech Med, as we expand beyond immunodiagnostics into biochemistry, hematology, and veterinary diagnostics. We are accelerating our efforts to diversify our future business portfolio and reinforce our global strategy for sustainable growth.”

• Showcased point-of-care solutions for latent tuberculosis and infection differentiation using the AFIAS platform
• Introduced 'ichroma 50 Plus,' an automated high-throughput device for latent tuberculosis diagnosis
• Aiming to expand partnerships and accelerate sales growth in the European market

Boditech Med, a leader in point-of-care diagnostics, announced that it unveiled its latest infectious disease diagnostic platforms at ESCMID Global 2025, held in Austria.

Organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), ESCMID Global is the world’s largest academic event dedicated to infectious diseases and clinical microbiology, attracting over 15,000 professionals from around 100 countries to share the latest research and technological advancements.

At the event, Boditech Med presented a range of point-of-care solutions targeting:

• Sepsis and severe infections
• Antimicrobial resistance (AMR)
• Tuberculosis
• Gastrointestinal health
• Tropical and global infectious diseases

Among the highlights were the AFIAS IGRA-TB for latent tuberculosis diagnosis and AFIAS MxA/CRP for viral-bacterial infection differentiation. These products drew strong interest for their rapid turnaround time, simple procedures, and high clinical utility.

AFIAS IGRA-TB is a rapid test kit that quantifies interferon-gamma to determine latent tuberculosis infection in just 15 minutes, dramatically reducing the complexity and labor-intensiveness associated with traditional IGRA testing. Its intuitive workflow makes it an ideal solution for field-focused global health programs.

Also launched at the event, the ichroma 50 Plus is a high-throughput device that fully automates the latent tuberculosis diagnostic process. Users can simply load the samples, and the device's system handles all subsequent steps automatically, significantly shortening testing time and offering a seamless, efficient diagnostic environment.

Meanwhile, AFIAS MxA/CRP is a next-generation infectious disease differentiation platform that simultaneously measures MxA protein (a viral infection marker) and CRP (a bacterial infection marker) using whole blood. Results are available within 12 minutes, providing a faster and more cost-effective alternative to traditional PCR or blood culture tests. This solution is also recognized as a valuable tool for improving infection management and reducing inappropriate antibiotic prescriptions, which are major contributors to antimicrobial resistance.

During ESCMID Global 2025, Boditech Med also hosted a successful Boditech Med Expert Dinner Meeting, inviting leading infectious disease experts from around the world. The meeting fostered in-depth discussions on the clinical applicability and diagnostic accuracy of Boditech’s products and sparked new opportunities for international collaborative research and partnerships.

Eui-yeol Choi, CEO of Boditech Med, commented:

“Accurate and rapid diagnostics are the cornerstone of global infectious disease response. Through this event, we aim to expand our partnerships across Europe and accelerate our sales growth in the European market.”

• Products classified as Class III high-risk medical devices; approved following local clinical performance evaluations
• Approval for dengue antigen and antibody kits enables detection of primary and secondary infections
• Entry into the Latin American infectious disease diagnostics market expected to drive revenue growth

Boditech Med, a leading provider of point-of-care diagnostics, announced on the 23rd that it has received product approval from Brazil’s National Health Surveillance Agency (ANVISA) for four diagnostic kits, including two for dengue fever and two for latent tuberculosis (LTBI).

The newly approved products include:

• ichroma™ Dengue NS1 Ag (antigen detection)

• ichroma™ Dengue IgG/IgM (antibody detection)

• ichroma™ IGRA-TB and AFIAS IGRA-TB for latent tuberculosis detection

These products have been classified as Class III high-risk medical devices under Brazilian regulations. In particular, the dengue diagnostic kits underwent local clinical performance evaluation as part of the approval process.

Dengue fever has emerged as a major global infectious disease, spreading across Asia, Latin America, and Africa due to climate change and urbanization, which have expanded mosquito habitats. According to the World Health Organization (WHO), more than 14 million cases were officially reported worldwide in 2024—over double the record-setting 2023 total. Brazil alone accounted for over 10 million cases, representing more than 70% of the global total. Unofficial estimates suggest that the actual global number of infections ranges between 100 million and 400 million annually.

While primary dengue infections may present mild symptoms such as fever, headache, and rash, secondary infections can trigger severe complications due to an excessive immune response. For this reason, a dual diagnostic approach using both antigen (NS1) and antibody (IgG/IgM) tests is clinically important. With this ANVISA approval, Boditech Med is now equipped with a complete diagnostic platform capable of differentiating between primary and secondary dengue infections.

Latent tuberculosis infection (LTBI) refers to a state where individuals are infected with Mycobacterium tuberculosis but do not exhibit symptoms or transmit the disease. However, 5–10% of LTBI carriers eventually develop active tuberculosis. According to WHO, over 10 million people contract tuberculosis each year, and approximately 25% of the global population is estimated to be latently infected. Brazil is one of the WHO-designated high-burden TB countries, with over 70,000 new cases reported annually.

Boditech Med’s IGRA-based diagnostic kits, which utilize the Interferon-Gamma Release Assay method, offer a fast and convenient solution for identifying LTBI. These tools are expected to play a critical role in enhancing early detection and preventing the progression to active tuberculosis, particularly in high-risk countries like Brazil.

Eui-yeol Choi, CEO of Boditech Med, stated:

“Brazil is a key player in the Latin American POCT market, and this approval represents a significant step in supporting the country’s efforts to combat both tuberculosis and dengue fever. Meeting ANVISA’s rigorous regulatory standards also reinforces confidence in our products and positions us for meaningful revenue growth in Brazil and the wider Latin American market.”